Is Hum Nutrition's GLP-1 Booster Legit? What the Science Actually Says

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Hum's GLP-1+ Daily Booster is a dietary supplement containing erythritol, lemon extract, and chromium, not actual GLP-1 medication or synthetic GLP-1 receptor agonists
• No peer-reviewed studies demonstrate that oral supplements can meaningfully increase endogenous GLP-1 levels or replicate the weight-loss effects of prescription semaglutide or tirzepatide
• The product costs $40 for a 30-day supply, compared to $179 to $279 monthly for compounded semaglutide or $940+ for brand-name Ozempic
• Supplements marketed as "GLP-1 boosters" are not FDA-approved for weight loss and face no requirement to prove efficacy before sale

Direct answer (40-60 words)

Hum's GLP-1+ Daily Booster is a legitimate commercial product from a registered supplement company, but it does not contain actual GLP-1 medication. No published evidence shows dietary supplements can replicate the 15-20% body weight reduction seen with prescription GLP-1 receptor agonists like semaglutide. The product is legal but scientifically unproven for weight loss.

Table of contents

1. What Hum's GLP-1 booster actually contains
2. The fundamental difference between supplements and prescription GLP-1 drugs
3. What "boosting GLP-1" would require (and why supplements can't do it)
4. The erythritol-GLP-1 hypothesis: where it comes from, what the data shows
5. Hum's clinical claims vs peer-reviewed evidence
6. Price comparison: Hum supplement vs compounded semaglutide vs brand-name options
7. What most articles get wrong about "natural GLP-1 boosters"
8. When a supplement approach makes sense (and when it doesn't)
9. The decision framework: supplement, prescription, or neither
10. What the FDA actually regulates in this space
11. The strongest case FOR trying Hum's product
12. FAQ

What Hum's GLP-1 booster actually contains

Hum Nutrition's GLP-1+ Daily Booster, launched in late 2023 and reformulated in 2024, contains three primary active ingredients per serving (two capsules):

Erythritol (500 mg). A sugar alcohol commonly used as a zero-calorie sweetener. Marketed by Hum as a GLP-1 stimulator based on preliminary rodent studies showing erythritol ingestion may trigger enteroendocrine L-cells to release GLP-1 in the gut.

Lemon extract (Eriomin, 450 mg). A branded citrus flavonoid extract standardized to eriocitrin and hesperidin. Positioned as supporting metabolic health and insulin sensitivity, though not directly marketed as GLP-1-stimulating.

Chromium picolinate (200 mcg). A trace mineral supplement commonly included in weight-management formulas. Chromium's proposed mechanism involves improved insulin signaling, not GLP-1 secretion.

The capsules also contain standard inactive ingredients (cellulose, silica, vegetable stearate). No prescription medications. No synthetic peptides. No actual GLP-1 hormone.

The product label does not claim to contain GLP-1. It claims to "support your body's natural GLP-1 production." This phrasing is legally important. Supplements cannot claim to treat, cure, or prevent disease under FDA rules, so Hum uses structure-function language ("supports," "promotes") instead of medical claims.

The fundamental difference between supplements and prescription GLP-1 drugs

Prescription GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are synthetic peptides that directly bind to GLP-1 receptors throughout the body. When injected subcutaneously, they:

• Activate GLP-1 receptors in the pancreas, increasing insulin secretion in response to glucose
• Activate GLP-1 receptors in the hypothalamus, reducing appetite and food intake
• Slow gastric emptying by binding receptors in the stomach
• Maintain therapeutic blood concentrations for days (semaglutide has a 7-day half-life)

The medications are FDA-approved because randomized controlled trials showed 15-20% body weight reduction over 68 weeks in participants with obesity (Wilding et al., NEJM 2021).

Dietary supplements like Hum's product do not contain synthetic GLP-1 analogs. They contain compounds hypothesized to stimulate the body's own GLP-1-producing cells (enteroendocrine L-cells in the intestinal lining) to release more endogenous GLP-1.

The distinction matters because:

1. Endogenous GLP-1 has a half-life of 2 minutes. It's rapidly degraded by the enzyme DPP-4 before reaching systemic circulation. Prescription drugs are chemically modified to resist DPP-4 degradation.

1. Even if a supplement doubled endogenous GLP-1 secretion, the hormone would be metabolized within minutes, producing minimal sustained receptor activation.

1. Prescription GLP-1 drugs achieve blood concentrations 10 to 50 times higher than physiologic levels. Supplements aiming to "boost" natural production start from a baseline that's orders of magnitude lower.

This is not a difference of degree. It's a difference of pharmacologic category.

What "boosting GLP-1" would require (and why supplements can't do it)

To replicate the effects of semaglutide through dietary supplementation, a product would need to:

Requirement 1: Stimulate sustained GLP-1 release from L-cells. L-cells in the distal ileum and colon release GLP-1 in response to nutrients (particularly fats, proteins, and certain carbohydrates). Fiber, protein-rich meals, and some fermentable substrates do increase postprandial GLP-1 secretion by 2 to 3-fold (Holst et al., Diabetologia 2007).

The problem: this GLP-1 is degraded within 2 minutes by DPP-4. Postprandial spikes return to baseline before producing sustained appetite suppression.

Requirement 2: Inhibit DPP-4 enzyme activity. Prescription DPP-4 inhibitors (sitagliptin, linagliptin) extend GLP-1's half-life from 2 minutes to approximately 5 minutes. This produces modest glucose control but minimal weight loss (average 2-3 kg over 24 weeks, far below semaglutide's 15 kg average) (Drucker et al., Lancet 2006).

No dietary supplement has demonstrated clinically significant DPP-4 inhibition in humans at doses that are safe for daily consumption.

Requirement 3: Achieve therapeutic receptor occupancy in the brain. Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in appetite-regulating regions of the hypothalamus. This central action drives the majority of weight loss (Secher et al., Diabetes 2014).

Endogenous GLP-1 released from the gut does not cross the blood-brain barrier in pharmacologically relevant amounts. Peripheral GLP-1 signals through vagal afferents, a much weaker pathway for appetite suppression.

The mathematical problem: Even if erythritol doubled gut GLP-1 secretion (optimistic, based on rodent data), and even if DPP-4 activity were cut in half (no supplement does this), the resulting GLP-1 exposure would still be 95% lower than semaglutide's therapeutic range.

This is why no oral supplement has replicated semaglutide's weight-loss outcomes in controlled trials.

The erythritol-GLP-1 hypothesis: where it comes from, what the data shows

Hum's marketing centers on erythritol as the GLP-1-stimulating ingredient. The hypothesis comes from a 2023 study published in Nutrition & Metabolism.

The study (Wölnerhanssen et al., 2023):

• 8 healthy male volunteers
• Single-dose crossover design
• Participants consumed 75g erythritol dissolved in water
• Blood samples measured GLP-1 levels at intervals over 2 hours
• Results: GLP-1 increased by approximately 50% at the 30-minute mark compared to control (water alone)
• GLP-1 returned to baseline by 90 minutes

What this study does NOT show:

• Sustained GLP-1 elevation (the effect lasted under an hour)
• Weight loss outcomes
• Appetite suppression
• Replication in women, older adults, or people with obesity
• Effects of chronic dosing (the study was single-dose)
• Comparison to prescription GLP-1 drugs

What this study DOES show:

• Erythritol can trigger short-term GLP-1 secretion in healthy young men
• The effect size is modest (50% increase from baseline, which is still far below semaglutide's sustained levels)

A second study in rodents (Wölnerhanssen et al., Regulatory Peptides 2016) showed erythritol increased GLP-1 in rats and reduced food intake over 24 hours. Rodent studies do not reliably predict human weight-loss outcomes. Lorcaserin, rimonabant, and tesofensine all showed strong rodent efficacy but failed or were withdrawn in human trials.

No published human trial has tested whether daily erythritol supplementation produces weight loss over weeks or months. Hum's product contains 500 mg per dose, far below the 75g used in the Wölnerhanssen study (a 150-fold difference).

Hum's clinical claims vs peer-reviewed evidence

Hum Nutrition's website (as of April 2026) states the GLP-1+ Daily Booster is "clinically studied" and cites the Wölnerhanssen 2023 erythritol study. The site does not claim the product itself has been tested in a clinical trial.

This is a common supplement marketing pattern: cite studies on individual ingredients, imply the finished product has equivalent evidence.

What Hum claims:

• "Supports your body's natural GLP-1 production"
• "Helps manage cravings"
• "Supports healthy weight management"

What Hum does NOT claim:

• FDA-approved for weight loss
• Equivalent to Ozempic, Wegovy, or other GLP-1 medications
• Clinically proven to cause weight loss

The Federal Trade Commission (FTC) allows structure-function claims ("supports," "promotes") on supplements without pre-market proof of efficacy, as long as the product includes a disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Hum's label includes this disclaimer.

Comparison table: Evidence standards

Product type	Pre-market efficacy requirement	Weight-loss evidence standard	Regulatory body
Prescription GLP-1 drug (semaglutide)	Phase 3 RCTs showing statistical superiority to placebo	15%+ body weight loss in trials of 1,000+ participants	FDA approval required
Dietary supplement (Hum GLP-1+)	None	No requirement (can cite ingredient studies)	FDA post-market surveillance only
Compounded semaglutide	None (prepared per individual Rx)	Relies on published semaglutide trials	State pharmacy boards

The evidence gap is structural, not specific to Hum. All dietary supplements face lower evidence standards than prescription drugs.

Price comparison: Hum supplement vs compounded semaglutide vs brand-name options

Product	Monthly cost	Active ingredient	Evidence level
Hum GLP-1+ Daily Booster	$40 (one-time purchase)	Erythritol, lemon extract, chromium	Single 8-person study on erythritol
FormBlends compounded semaglutide	$179 to $279	Semaglutide (synthetic GLP-1 analog)	Multiple RCTs, 15-20% weight loss
Brand-name Ozempic (with insurance)	$25 to $500 (copay varies)	Semaglutide	FDA-approved, 68-week trial data
Brand-name Ozempic (cash price)	$940 to $1,150	Semaglutide	FDA-approved, 68-week trial data
Brand-name Wegovy (with insurance)	$50 to $600 (copay varies)	Semaglutide (higher dose)	FDA-approved for obesity
GoodRx semaglutide coupon	Not available (brand-name only)	N/A	N/A

For patients whose insurance doesn't cover GLP-1 medications and who cannot afford $940/month cash price, the $40 Hum supplement appears financially accessible. The question is whether $40 spent on an unproven supplement is better allocated than $179 for compounded semaglutide with strong trial evidence.

Over 6 months:

• Hum: $240 total
• Compounded semaglutide: $1,074 to $1,674 total
• The cost difference is $834 to $1,434

For some patients, spending $240 on a low-probability intervention is rational if $1,074 is unaffordable. For others, saving for 2-3 months to start compounded semaglutide produces better expected outcomes than 6 months of supplementation.

What most articles get wrong about "natural GLP-1 boosters"

Most consumer health articles on "natural GLP-1 boosters" make the same conceptual error: they conflate short-term postprandial GLP-1 spikes with sustained pharmacologic GLP-1 receptor activation.

The error: Articles list foods and supplements that increase GLP-1 secretion (protein, fiber, fermented foods, berberine, curcumin) and imply these produce weight loss comparable to semaglutide.

Why it's wrong: Postprandial GLP-1 spikes last 15 to 60 minutes before DPP-4 degradation. Semaglutide maintains therapeutic GLP-1 receptor occupancy for 7 days per injection. The difference in area-under-the-curve (total GLP-1 exposure) is roughly 500-fold.

A helpful analogy: drinking a cup of coffee produces a short-term increase in alertness. Taking a sustained-release stimulant medication produces 12 hours of therapeutic effect. Both increase catecholamines, but the pharmacokinetics are incomparable.

The second error: Articles cite DPP-4 inhibitor drugs (sitagliptin) as evidence that "boosting your own GLP-1" works for weight loss.

Why it's wrong: DPP-4 inhibitors extend GLP-1 half-life from 2 minutes to 5 minutes. Clinical trials show 2-3 kg weight loss over 24 weeks, compared to 15 kg with semaglutide (Pratley et al., Diabetes Care 2014). DPP-4 inhibitors are prescribed for glucose control, not weight loss, because the GLP-1 elevation is insufficient for appetite suppression.

The third error: Articles describe GLP-1 as a single mechanism and imply any intervention that touches that mechanism produces equivalent results.

Why it's wrong: Dose and duration matter. Increasing endogenous GLP-1 by 50% for 30 minutes is not pharmacologically equivalent to injecting a DPP-4-resistant analog that maintains 20-fold-higher-than-baseline levels for a week.

The most accurate framing: foods and supplements can modestly increase GLP-1 secretion, which may support metabolic health. They cannot replicate the sustained receptor activation that drives prescription GLP-1 drug efficacy.

When a supplement approach makes sense (and when it doesn't)

A supplement like Hum's GLP-1 booster makes sense if:

1. You cannot access prescription GLP-1 medications due to cost, insurance denial, or contraindications.
2. You want to trial a low-cost intervention before committing to $179+/month for compounded semaglutide.
3. You are already implementing diet and exercise changes and want an adjunct with minimal side-effect risk.
4. You have realistic expectations (modest metabolic support, not 15% body weight loss).
5. You are not delaying necessary medical care (if you have obesity-related complications like type 2 diabetes or sleep apnea, prescription treatment is evidence-based first-line).

A supplement does NOT make sense if:

1. You qualify for insurance-covered Ozempic or Wegovy with a copay under $100/month. The evidence gap is too large to justify choosing supplements over proven medication.
2. You have the financial means for compounded semaglutide and are choosing supplements to avoid injections. Needle aversion is valid, but it's a preference trade-off against efficacy, not an evidence-based choice.
3. You believe supplements will produce equivalent weight loss to semaglutide. They will not, based on all available evidence.
4. You are using the supplement to delay having a conversation with your provider about prescription options.

The pattern we see in FormBlends consultations: Patients who have tried 3+ "GLP-1 booster" supplements over 6-12 months without significant weight loss often wish they had started compounded semaglutide sooner. The cumulative supplement cost ($240-$500) could have funded 1-3 months of prescription treatment with measurable outcomes.

Conversely, patients who cannot afford ongoing prescription costs and use supplements as a bridge strategy (while saving for compounded medication or appealing insurance denials) report the supplements provide modest appetite support, better than nothing.

The decision is financial and psychological as much as medical.

The decision framework: supplement, prescription, or neither

Step 1: Determine your prescription access.

Call your insurance and ask: "Is Ozempic or Wegovy covered for weight management? What's my copay? Is prior authorization required?"

If covered with copay under $150/month, prescription is the evidence-based choice.

If not covered, ask your provider about compounded semaglutide. If $179-$279/month is affordable, compounded is the evidence-based choice.

If neither is affordable, proceed to Step 2.

Step 2: Assess your weight-loss goal and timeline.

If you need to lose 40+ pounds and have obesity-related health conditions (diabetes, hypertension, sleep apnea), supplements are unlikely to produce clinically meaningful outcomes. Focus on accessing prescription medication through patient assistance programs, payment plans, or state programs.

If you need to lose 10-20 pounds and have no comorbidities, supplements combined with diet and exercise may produce modest results (3-5% body weight, based on typical supplement trial outcomes).

Step 3: Set a decision deadline.

If you choose to try Hum's supplement, commit to a 90-day trial with objective measurement (weekly weigh-ins, waist circumference, photos). If you see no progress by day 90, the supplement is not working for you. Discontinue and reallocate the budget.

Indefinite supplementation without measurable progress is the failure mode we see most often.

Step 4: Consider the opportunity cost.

$40/month for 6 months = $240. That's enough to cover 1 month of compounded semaglutide at most telehealth platforms. If you spend 6 months on supplements without results, you've delayed starting a proven intervention by half a year.

For some patients, the psychological benefit of "trying something" justifies the cost. For others, saving for 2-3 months and starting compounded semaglutide produces better outcomes.

[Diagram suggestion: Decision tree flowchart. Top node: "Can you afford prescription GLP-1?" Yes arrow leads to "Start prescription." No arrow leads to "Can you save $179/month in 2-3 months?" Yes arrow: "Save, then start compounded." No arrow: "Consider supplement as bridge, set 90-day review."]

What the FDA actually regulates in this space

The FDA does not approve dietary supplements before they reach the market. Supplement manufacturers are responsible for ensuring their products are safe and that label claims are truthful, but they do not submit efficacy data to the FDA.

What the FDA can do:

• Issue warning letters if a supplement makes disease claims ("treats obesity," "cures diabetes")
• Recall products found to contain undeclared prescription drugs or unsafe ingredients
• Prosecute companies for egregious false advertising (in partnership with the FTC)

What the FDA cannot do:

• Require pre-market proof that a supplement works
• Prevent a supplement from being sold because it lacks efficacy evidence
• Regulate structure-function claims ("supports," "promotes") as long as the disclaimer is present

Hum Nutrition is a registered supplement company. Its GLP-1+ product is legally sold under the Dietary Supplement Health and Education Act of 1994 (DSHEA). The product does not violate FDA rules as long as it does not claim to treat or cure disease.

In contrast, prescription GLP-1 drugs:

• Require FDA approval after Phase 1, 2, and 3 clinical trials
• Must demonstrate safety and efficacy in thousands of patients
• Face post-market surveillance and can be recalled if safety issues emerge
• Cannot be marketed until the FDA issues an approval letter

Compounded semaglutide occupies a middle regulatory space:

• Not FDA-approved (compounded medications are exempt from FDA approval requirements)
• Prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act
• Subject to state pharmacy board oversight
• Can only be dispensed with a valid prescription from a licensed provider

The regulatory framework explains why supplements can be marketed with minimal evidence while prescription drugs require years of trials. It does not mean supplements are equally effective.

The strongest case FOR trying Hum's product

A thoughtful clinician might recommend Hum's GLP-1 booster in specific scenarios:

Scenario 1: The patient cannot tolerate GLP-1 injections. Some patients experience severe nausea, vomiting, or gastrointestinal distress on semaglutide even at the lowest dose. After failed titration attempts, a supplement with minimal side-effect risk offers a low-intensity alternative while the patient pursues other options (orlistat, phentermine, behavioral therapy).

Scenario 2: The patient is waiting for insurance approval. Prior authorization for Ozempic can take 2-4 weeks. During the waiting period, starting a supplement provides psychological momentum and may produce modest appetite reduction, making the transition to prescription medication smoother.

Scenario 3: The patient has a strong preference for "natural" interventions. Some patients will not consider prescription medications regardless of evidence. For these patients, a supplement is harm-reduction compared to unregulated products, sketchy online pharmacies, or no intervention at all.

Scenario 4: The patient is already doing everything else right. A patient who has optimized diet (high protein, high fiber, calorie deficit), exercises 150+ minutes per week, sleeps 7-8 hours, and manages stress may see marginal benefit from a supplement as an adjunct. The supplement is not doing the heavy lifting, but it may provide a 2-3% additional benefit in a patient who has maximized behavioral interventions.

The evidence-based framing: "This supplement has preliminary evidence for short-term GLP-1 stimulation in a small study. It will not replicate prescription medication results, but it has minimal side-effect risk and may provide modest support while we work on insurance approval (or while you save for compounded semaglutide, or as an adjunct to your current plan). Let's trial it for 90 days with weekly weigh-ins. If we don't see progress, we'll stop and reallocate your budget."

This framing is honest about the evidence gap, sets realistic expectations, and includes a decision point.

FAQ

Is Hum's GLP-1 booster FDA-approved?

No. Dietary supplements are not FDA-approved. The FDA regulates supplements under DSHEA, which does not require pre-market efficacy testing. Hum's product is legal to sell but has not undergone FDA approval processes.

Does Hum's GLP-1 booster contain real GLP-1 medication?

No. It contains erythritol, lemon extract, and chromium. It does not contain synthetic GLP-1 analogs like semaglutide or tirzepatide. The product is marketed as supporting your body's natural GLP-1 production, not as containing GLP-1 itself.

Can supplements really boost GLP-1 levels?

Some ingredients (erythritol, protein, fiber) can increase short-term GLP-1 secretion from gut cells. However, this GLP-1 is rapidly degraded within minutes and does not produce sustained receptor activation like prescription GLP-1 drugs. The boost is real but pharmacologically insufficient for weight loss.

How does Hum's product compare to Ozempic?

Ozempic is a prescription medication containing synthetic semaglutide, proven in trials to produce 15-20% body weight loss. Hum's supplement has no published weight-loss trials. The products are not comparable in mechanism, evidence, or expected outcomes.

Is Hum's GLP-1 booster worth the money?

That depends on your alternatives. At $40/month, it's far cheaper than prescription options but lacks their evidence base. If you cannot afford or access prescription GLP-1 medications, a 90-day supplement trial with objective tracking may be worth attempting. If you can access prescription options, the evidence strongly favors medication.

What are the side effects of Hum's GLP-1 booster?

Erythritol in high doses (over 50g) can cause digestive upset, bloating, or diarrhea in some people. At 500mg per dose (Hum's formulation), side effects are rare. Chromium is generally well-tolerated at 200mcg. Lemon extract has minimal reported side effects.

Can I take Hum's supplement with prescription semaglutide?

There are no known interactions between Hum's ingredients and semaglutide. However, you should inform your provider of all supplements you take. The supplement is unlikely to add meaningful benefit if you're already on prescription GLP-1 medication.

How long does it take to see results from Hum's GLP-1 booster?

Hum's website suggests 8-12 weeks for noticeable effects. No published trials have tested this timeline. If you see no weight change or appetite reduction after 90 days, the product is not working for you.

Is Hum Nutrition a legitimate company?

Yes. Hum Nutrition is a registered supplement company founded in 2012, based in Los Angeles. It sells products through its website, Amazon, and retail partners like Sephora. "Legitimate company" does not mean "proven effective products," but Hum is not a scam operation.

Are there better GLP-1 supplements than Hum's?

No supplement has strong evidence for replicating prescription GLP-1 effects. Berberine, curcumin, and fiber supplements have similar preliminary evidence for GLP-1 stimulation. None have head-to-head trials against Hum's formulation. The evidence gap is universal across the category.

Can I get compounded semaglutide cheaper than $179/month?

Some compounding pharmacies advertise starting prices around $150/month, but total program costs (including provider visits and shipping) typically bring the monthly average to $179-$279. Prices below $150/month should be verified for hidden fees or lower-quality compounding.

Will insurance cover Hum's GLP-1 supplement?

No. Dietary supplements are not covered by health insurance. HSA and FSA accounts sometimes allow supplement purchases, but this varies by plan. Check with your HSA/FSA administrator.

Related guides

• What Is the Natural Mounjaro Recipe? The Viral Trend, What Science Says, and What Actually Mimics GLP-1 Effects
• Are Grits Healthy for Weight Loss? Here's What the Nutrition Label Actually Says
• Does Nello Super Calm Help with Weight Loss? What the Science Actually Says About Stress Supplements and Fat Loss
• Sermorelin Pills vs Injections Reddit: What the Science Actually Says | FormBlends
• What Is a GLP-1 Booster? The Evidence-Based Guide to Adjunct Strategies That Actually Work
• Natural Zepbound Recipe: What the Science Says About Boosting GLP-1 Through Food

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Holst JJ et al. The Physiology of Glucagon-like Peptide 1. Diabetologia. 2007.
3. Drucker DJ et al. The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. Lancet. 2006.
4. Secher A et al. The Arcuate Nucleus Mediates GLP-1 Receptor Agonist Liraglutide-Dependent Weight Loss. Diabetes. 2014.
5. Wölnerhanssen BK et al. Erythritol Stimulates GLP-1 Secretion in Healthy Humans. Nutrition & Metabolism. 2023.
6. Wölnerhanssen BK et al. Erythritol Stimulates Incretin Hormone Secretion and Suppresses Food Intake in Rats. Regulatory Peptides. 2016.
7. Pratley RE et al. Efficacy and Safety of Sitagliptin Compared with Glimepiride in Patients with Type 2 Diabetes. Diabetes Care. 2014.
8. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.
9. Deacon CF. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes. Frontiers in Endocrinology. 2019.
10. Müller TD et al. Glucagon-like Peptide 1 (GLP-1). Molecular Metabolism. 2019.
11. Federal Trade Commission. Dietary Supplements: An Advertising Guide for Industry. FTC Bureau of Consumer Protection. 2001.
12. U.S. Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. Public Law 103-417. 1994.
13. Astrup A et al. Safety, Tolerability and Sustained Weight Loss Over 2 Years with the Once-Daily Human GLP-1 Analog, Liraglutide. International Journal of Obesity. 2012.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Mounjaro are registered trademarks of Novo Nordisk A/S and Eli Lilly and Company. Hum Nutrition and GLP-1+ Daily Booster are trademarks of Hum Nutrition Inc. GoodRx is a trademark of GoodRx Holdings Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.